StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH – Free Report) in a research note issued to investors on Saturday. The firm issued a sell rating on the stock.
Bio-Path Price Performance
Shares of NASDAQ BPTH opened at $0.80 on Friday. Bio-Path has a 12-month low of $0.61 and a 12-month high of $12.37. The stock’s 50 day simple moving average is $0.98 and its 200 day simple moving average is $1.55.
Hedge Funds Weigh In On Bio-Path
An institutional investor recently bought a new position in Bio-Path stock. Armistice Capital LLC acquired a new stake in Bio-Path Holdings, Inc. (NASDAQ:BPTH – Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm acquired 97,000 shares of the company’s stock, valued at approximately $194,000. Armistice Capital LLC owned about 4.66% of Bio-Path as of its most recent SEC filing. Institutional investors and hedge funds own 5.74% of the company’s stock.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Further Reading
- Five stocks we like better than Bio-Path
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Super Micro Computer Soars 28%: Is It Really Out of the Woods?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Traders Are Flocking Back to Oil: What’s Fueling the Optimism
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Hot Stock Trends to Ride Into 2025
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
